Alemtuzumab
Showing 1 - 25 of 419
Reduced-dose Alemtuzumab for Kidney Transplant Rejection
Not yet recruiting
- Kidney Transplant Rejection
- (no location specified)
Oct 25, 2023
Predict T Cell Chimerism After MSD SCT for SCD?
Recruiting
- Sickle Cell Disease
- Alemtuzumab Injection [Campath]
-
Amsterdam, NetherlandsAmsterdam Medical Centre
Jun 20, 2023
Allogeneic Hematopoietic Cell Transplantation Trial (Alemtuzumab)
Not yet recruiting
- Allogeneic Hematopoietic Cell Transplantation
- Alemtuzumab
- (no location specified)
Aug 12, 2022
Hodgkin Lymphoma, DLBCL Trial run by the NCI (campath, Rituximab, EPOCH)
Completed
- Hodgkin Lymphoma
- Diffuse Large B-Cell Lymphoma
- Campath
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 11, 2022
T-cell-prolymphocytic Leukemia Trial in Cologne (Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab, Alemtuzumab)
Completed
- T-cell-prolymphocytic Leukemia
- Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab
- Alemtuzumab
-
Cologne, GermanyUniversity Hospital Cologne
Dec 16, 2021
Chronic Granulomatous Disease Trial run by the NIAID (Sirolimus, Cyclophosphamide, Alemtuzumab)
Recruiting
- Chronic Granulomatous Disease
- Sirolimus
- +7 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jul 23, 2022
Leukemia Trial in Houston (Alemtuzumab, Etoposide, Dexamethasone)
Active, not recruiting
- Leukemia
- Alemtuzumab
- +5 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Feb 2, 2022
B-cell Chronic Lymphocytic Leukemia Trial in Peking (Alemtuzumab)
Suspended
- B-cell Chronic Lymphocytic Leukemia
- Alemtuzumab
-
Peking, Beijing, ChinaPeking University Cancer Hospital
Jun 15, 2022
Relapsing-Remitting Multiple Sclerosis Trial in Hamburg, Mannheim (Autologous Hematopoietic Stem Cell Transplantation,
Terminated
- Relapsing-Remitting Multiple Sclerosis
- Autologous Hematopoietic Stem Cell Transplantation
- +2 more
-
Hamburg, Germany
- +1 more
Mar 1, 2022
B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma Trial in Columbus (Letermovir)
Recruiting
- B-Cell Prolymphocytic Leukemia
- +5 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 18, 2022
T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL), Peripheral T-Cell Lymphoma (PTCL) Trial run by the NCI (IL-15 plus,
Completed
- T-Cell Lymphoma Relapsed
- +4 more
- IL-15 plus
- alemtuzumab
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Apr 27, 2022
Leukemia, Lymphocytic, Chronic, B-Cell Trial in Austria (Bendamustine, Alemtuzumab)
Completed
- Leukemia, Lymphocytic, Chronic, B-Cell
- Bendamustine
- Alemtuzumab
-
Innsbruck, Tirol, Austria
- +6 more
Feb 15, 2022
Adding Azathioprine/Hydroxyurea Preconditioning to
Recruiting
- Sickle Cell Disease
- Preconditioning with azathiprine and hydroxyurea (3 months)
-
Amsterdam, NetherlandsAmsterdam Medical Centre
Feb 9, 2022
Multiple Sclerosis, Relapsing-Remitting Trial in Münster (Alemtuzumab)
Completed
- Multiple Sclerosis, Relapsing-Remitting
- Alemtuzumab
-
Münster, GermanyUniversitätsklinikum Münster, Klinik für Allgemeine Neurologie
Oct 25, 2021
Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell Trial run by the NCI (Alemtuzumab (Campath), EPOCH)
Completed
- Lymphoma, T-Cell
- Lymphoma, Extranodal NK-T-Cell
- Alemtuzumab (Campath)
- EPOCH
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Feb 3, 2022
Sickle Cell Disease Trial in Duarte (drug, procedure, radiation)
Recruiting
- Sickle Cell Disease
- Alemtuzumab
- +3 more
-
Duarte, CaliforniaCity of Hope Comprehensive Cancer Center
Jul 31, 2022
Czech Pharmaco-epidemiological Study on Disease Modifying Drugs
Completed
- Multiple Sclerosis
- interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
-
Prague, CzechiaIMPULS Endowment Fund
Mar 7, 2023
Sickle Cell Disease Trial in Memphis (hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and
Recruiting
- Sickle Cell Disease
- hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus
- hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus
-
Memphis, TennesseeSt. Jude Children's Research Hospital
May 5, 2022
Sickle Cell Disease Trial in Hackensack (Alemtuzumab, Fludarabine, Melphalan)
Active, not recruiting
- Sickle Cell Disease
- Alemtuzumab
- +3 more
-
Hackensack, New JerseyHackensack University Medical Center
Feb 4, 2022
Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate
Recruiting
- Multiple Sclerosis
- Diroximel Fumarate
- +8 more
-
Eden Prairie, MinnesotaOptumInsight
Jan 9, 2023
Multiple Sclerosis Trial in Worldwide (Alemtuzumab GZ402673, Glatiramer acetate, Beta-Interferon)
Active, not recruiting
- Multiple Sclerosis
- Alemtuzumab GZ402673
- +11 more
-
Wien, Austria
- +20 more
Jun 16, 2022
Secondary Malignant Tumor of Retroperitoneum, Secondary Malignant Tumor of Peritoneum, Pseudomyxoma Peritonei Trial in Cleveland
Not yet recruiting
- Secondary Malignant Neoplasm of Retroperitoneum
- +2 more
- Intestinal, Multivisceral or Modified Multivisceral Transplantation
- +3 more
-
Cleveland, OhioCleveland Clinic Digestive Disease & Surgery Institute (DDSI), C
Oct 10, 2023
Sickle Cell Anemia Trial run by the NHLBI (PBSC Transplant, Alemtuzumab, Sirolimus)
Active, not recruiting
- Sickle Cell Anemia
- PBSC Transplant
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Oct 13, 2022